Potential adverse events with biologic response modifiers.
In recent years, an explosion of biologic response modifiers has entered the market to combat a variety of immune-mediated diseases. These can be in the form of recombinant cytokines, as in the case of interferon beta in the treatment of multiple sclerosis, or novel engineered antibodies constructed by combining non-human determinants with a human immunoglobulin scaffold, as in the case of omalizumab in the treatment of allergic asthma. More recently, completely human monoclonal antibodies have also been constructed. Adverse reactions related to these agents can be classified as expected or unexpected events. A number of case studies and a handful of randomized trials have demonstrated the potential toxicities with the use of biologic response modifiers. This article aims to review adverse event profiles of select biologic response modifiers for which the most data is available and are common to a rheumatology, allergy/immunology, and dermatology patient population.
Kong
James S W
JS
Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California, Davis, California 95616, USA.
Teuber
Suzanne S
SS
Gershwin
M Eric
ME
D000818:Animals; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy*; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*
D016207:Cytokines; D007155:Immunologic Factors